Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Multiple Myeloma 58Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 23Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Recurrence 16Lymphoma, Non-Hodgkin 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 10Neoplasms, Plasma Cell 9Waldenstrom Macroglobulinemia 6Hodgkin Disease 6Neoplasms 5Leukemia, Myeloid, Acute 5Burkitt Lymphoma 5Lymphoma, T-Cell 4Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Anaplastic 3Leukemia 3Hematologic Neoplasms 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 24Cyclophosphamide 23Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × Lenalidomide × Clear all
NCT00903630 2017-12-28

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
15 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00179712 2016-12-01

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Celgene Corporation

Phase 1/2 Completed
60 enrolled
Gynecologic

Ovarian Neoplasms

NCT00179725 2006-04-12

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Celgene

Phase 1/2 Terminated
60 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡